All News

FDA3.jpg

Filgotinib Bows Out of the RA Race in the USA

Jack Cush, MD

Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).

Read Article
JAK Janus

Consensus Recommendations on JAK Inhibitor Use

Jack Cush, MD

A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Stop These COVID Mistakes (12.11.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
covid.corona

Rheumatic Disease and COVID-19: Who Is at Risk?

MedPage Today

Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.

Read Article
Psoriasis Severe legs sara

Systemic Steroids Seldom Flare Psoriasis

Jack Cush, MD

A tenet of drug management suggests that steroid use in psoriasis may be associated with rebound flares; well this has been challenged by a new observational trial showing that the risk of flares (and severe flares) of psoriasis flares were seldom triggered by systemic steroids - certainly much l

Read Article
pso.PsA_.NPF_.jpg

Upadacitinib Effective in Biologic Refractory Psoriatic Arthritis

Jack Cush, MD

The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.

Read Article
A closer Look at PsA Measures and Outcomes

Measuring Disease Activity in PsA: Dr. Eric Ruderman

Eric Ruderman, MD

In this video, Dr. Eric Ruderman looks at abstracts #0884, #0323 and #0909, which focus on disease activity measurement in psoriatic arthritis, presented at the 2020 ACR Convergence meeting earlier this month. 

Read Article
Enthesitis in PsA: Dr. Robert Chao ( @doctorRBC) #ACR20 https://t.co/eSnkat99rP https://t.co/cgzqdeDiU0

Links:

Dr. John Cush RheumNow ( View Tweet)
The EMA's CHMP has recommended upadacitinib (Rinvoq) as an indication for the treatment of adults with active Psoriatic Arthritis and Ankylosing Spondylitis. https://t.co/0PKm90mo7F

Links:

Dr. John Cush RheumNow ( View Tweet)

Upadacitinib Effective in Biologic Refractory Psoriatic Arthritis #ACR20 https://t.co/uE4ZmfulbP https://t.co/OzpX6hLw6O

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @doctorRBC : Deucravacitinib TYK2i for PsA Phase2b 16wk, Double-blind, Placebo, RCT ⬆️ACR20/50/70 response vs. PBO ⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO *⃣No serious AE @RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/LeMBj3XQo4" https://t.co/U9fB5hgcJY

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Ruderman ( @JointMD) discusses a new pathway - the use of deucravacitinib - to treat psoriatic arthritis at #ACR20. https://t.co/1uz47jKVPv https://t.co/1I5B14w9Ox

Links:

Dr. John Cush RheumNow ( View Tweet)
Measuring Disease Activity in Psoriatic Arthritis: Dr. Eric Ruderman ( @JointMD) looks at several abstracts that focus on disease activity measurement in psoriatic arthritis presented at the #ACR20 meeting. https://t.co/Tu58NDbc51 https://t.co/RGwON4gu7w

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @doctorRBC : Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms #ACR20 Abs#2026 https://t.co/n5wcKK1juC
Dr. John Cush RheumNow ( View Tweet)
Listen to our latest QD podcast on differential Dx of Arthritis in HIV+ individuals, possibilities with hyperuricemia in Psoriatic Arthritis MDA5 myositis reviewed, difficult RA with serious infections and limited options. https://t.co/HGjgkMmOzp https://t.co/jFs8kINS3U

Links:

Dr. John Cush RheumNow ( View Tweet)
PROs in Psoriatic Arthritis: Dr. Antoni Chan ( @synovialjoints) reviews abstract #0169 presented at #ACR20. https://t.co/hTlrZMNnab https://t.co/HMOMnT36zf

Links:

Dr. John Cush RheumNow ( View Tweet)
Swollen Joints Associated with Ultrasound Synovitis in PsA by Dr. Robert Chao (@ @doctorRBC) #ACR20 https://t.co/cRBuzrfEpt https://t.co/sgoqsmEyCJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Chicago-based Dr. Eric Ruderman discussed the shifting treatment paradigms in psoriatic arthritis by reviewing abstracts #0504 and #2026 at #ACR20. https://t.co/jsLkgWG63v https://t.co/gLgzjyCWct

Links:

Dr. John Cush RheumNow ( View Tweet)
Listen to our Psoriatic Arthritis Panel Discussion podcast with Drs. Artie Kavanaugh, Jack Cush, Eric Ruderman and Alexis Ogdie-Beatty. #ACR20 Listen via the link below or Apple/Android podcasts. https://t.co/BbOyuM4kZV https://t.co/7Y1b6vmYy8

Links:

Dr. John Cush RheumNow ( View Tweet)
Long-Term Benefits of Ixekizumab in Psoriatic Arthritis https://t.co/CaGVSvFzVd https://t.co/ktdG5nt96f

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×